The national mental health crisis continues to worsen.
In a recent speech, a senior official at the U.S. Department of Justice Antitrust Division noted that “in U.S. antitrust enforcement and competition policy, there is no more important question than what can we do to safeguard competition in the health care industry.”
Three years following the onset of the COVID-19 public health emergency (PHE), states across the United States continue to enact permanent changes to telehealth laws that impact how physicians and other providers can deliver care remotely.
High-quality primary care is foundational to providing “whole person care” that emphasizes prevention, as well as team-based and relationship-based care.
The COVID-19 pandemic catalyzed a dramatic rise in the use of telehealth nationwide to deliver health care services to Medicaid and Children’s Health Insurance Program enrollees.
The COVID-19 pandemic exacerbated the serious and growing mental health and substance use disorder crisis gripping children and youth in the United States.
The inclusion of racial and ethnic groups in clinical trials has been a national priority for decades, but progress toward that goal has been limited.
After the enactment of the Inflation Reduction Act, which enables Medicare to negotiate the price of certain prescription drugs, Congress is again attempting to lower the cost of prescription drugs.
Over the past few years, there has been tightening enforcement and numerous lawsuits driven by the increasingly complex web of federal and state anti-kickback and anti-inducement statutes.
From the end of the COVID-19 public health emergency (PHE) to the overturning of Roe v. Wade to the skyrocketing growth of virtual care, multiple forces are converging to remap the health care landscape.